Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma

NCT01838200 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped Slow recruitment due to changes in standard of care

Conditions

Metastatic Melanoma

Interventions

BIOLOGICAL: Bacillus Calmette-Guérin (BCG) vaccine
DRUG: Ipilimumab
DRUG: Isoniazid

Sponsor

Ludwig Institute for Cancer Research

Collaborators

[object Object]